Characterising phospholipids and free fatty acids in patients with schizophrenia: A case-control study

References

• Addington J, Addington D. 1999. Neurocognitive and social functioning in schizophrenia. Schizophr Bull. 25(1):173–182.
   PubMed Web of Science ®Google Scholar
• Brosche T, Brueckmann M, Haase KK, Sieber C, Bertsch T. 2007. Decreased plasmalogen concentration as a surrogate marker of oxidative stress in patients presenting with acute coronary syndromes or supraventricular tachycardias. Clin Chem Lab Med. 45(5):689–691.
   PubMed Web of Science ®Google Scholar
• Bylesj M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. 2006. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J Chemometrics. 20(8–10):341–351.
   Web of Science ®Google Scholar
• Cao B, Wang D, Brietzke E, McIntyre RS, Pan Z, Cha D, Rosenblat JD, Zuckerman H, Liu Y, Xie Q, et al. 2018. Characterizing amino-acid biosignatures amongst individuals with schizophrenia: a case-control study. Amino acids. 50(8):1013–1023.
   PubMed Web of Science ®Google Scholar
• Castillo RI, Rojo LE, Henriquez-Henriquez M, Silva H, Maturana A, Villar MJ, Fuentes M, Gaspar PA. 2016. From molecules to the clinic: linking schizophrenia and metabolic syndrome through sphingolipids metabolism. Front Neurosci. 10:488.
   PubMed Web of Science ®Google Scholar
• Chadeau-Hyam M, Ebbels TMD, Brown IJ, Chan Q, Stamler J, Huang CC, Daviglus ML, Ueshima H, Zhao L, Holmes E, et al. 2010. Metabolic profiling and the metabolome-wide association study: significance level for biomarker identification. J Proteome Res. 9(9):4620–4627.
   PubMed Web of Science ®Google Scholar
• Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 60(5):443–456.
   PubMed Web of Science ®Google Scholar
• Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. 2011. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 111(10):6130–6185.
   PubMed Web of Science ®Google Scholar
• Engelmann B, Bräutigam C, Kulschar R, Duhm J, Prenner E, Hermetter A, Richter WO, Thiery J, Seidel D. 1994. Reversible reduction of phospholipid bound arachidonic acid after low density lipoprotein apheresis. Evidence for rapid incorporation of plasmalogen phosphatidylethanolamine into the red blood cell membrane. Biochim Biophys Acta. 1196(2):154–164.
   PubMed Web of Science ®Google Scholar
• Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP, Smith GN, Arango V, Mann JJ, Dwork AJ, et al. 2003. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry. 8(9):811–820.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Dyer RA, Beasley CL. 2017. Evidence for altered cell membrane lipid composition in postmortem prefrontal white matter in bipolar disorder and schizophrenia. J Psychiatr Res. 95:135–142.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Liencres C, Tas C, Brown EC, Erdin S, Onur E, Cubukcoglu Z, Aydemir O, Esen-Danaci A, Brüne M. 2014. Oxidative stress in schizophrenia: a case-control study on the effects on social cognition and neurocognition. BMC Psychiatry. 14:268
   PubMed Web of Science ®Google Scholar
• Gu H, Gowda GA, Raftery D. 2012. Metabolic profiling: are we en route to better diagnostic tests for cancer? Future Oncol. 8(10):1207–1210.
   PubMed Web of Science ®Google Scholar
• Hamazaki K, Choi KH, Kim HY. 2010. Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species. J Psychiatr Res. 44(11):688–693.
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Lei J, Matsumoto T, Onishi S, Suemori K, Yasukawa M. 2011. Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-β production. Biochem Biophys Res Commun. 415(3):526–531.
   PubMed Web of Science ®Google Scholar
• Holmes E, Wilson ID, Nicholson JK. 2008. Metabolic phenotyping in health and disease. Cell. 134(5):714–717.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, McEvoy J, Baillie R, Zhu H, K Yao J, Nimgaonkar VL, Buckley PF, Keshavan MS, Georgiades A, Nasrallah HA, et al. 2012. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res. 198(3):347–352.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KRR. 2007. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 12(10):934–945.
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. 1993. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res. 49(1):89–95.
   PubMed Web of Science ®Google Scholar
• Koerkamp MG, Rep M, Bussemaker HJ, Hardy GPMA, Mul A, Piekarska K, Szigyarto CA-K, De Mattos JMT, Tabak HF. 2002. Dissection of transient oxidative stress response in Saccharomyces cerevisiae by using DNA microarrays. Mol Biol Cell. 13(8):2783–2794.
   PubMed Web of Science ®Google Scholar
• Leppik L, Parksepp M, Janno S, Koido K, Haring L, Vasar E, Zilmer M. 2020. Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci. 270(1):59–70.
   PubMed Web of Science ®Google Scholar
• Liu X, Zheng P, Zhao X, Zhang Y, Hu C, Li J, Zhao J, Zhou J, Xie P, Xu G, et al. 2015. Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry. J Proteome Res. 14(5):2322–2330.
   PubMed Web of Science ®Google Scholar
• Mahadevan S, Shah SL, Marrie TJ, Slupsky CM. 2008. Analysis of metabolomic data using support vector machines. Anal Chem. 80(19):7562–7570.
   PubMed Web of Science ®Google Scholar
• McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, Dougherty GG, Yao JK, Kaddurah-Daouk R. 2013. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One. 8(7):e68717
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, Welham J. 2008. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 30:67–76.
   PubMed Web of Science ®Google Scholar
• Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D. 2017. Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis. Schizophr Res. 190:18–27.
   PubMed Web of Science ®Google Scholar
• Nigam S, Schewe T. 2000. Phospholipase A(2)s and lipid peroxidation. Biochim Biophys Acta. 1488(1–2):167–181.
   PubMed Web of Science ®Google Scholar
• Nuss P, Tessier C, Ferreri F, De Hert M, Peuskens J, Trugnan G, Masliah J, Wolf C. 2009. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia. Psychiatry Res. 169(2):91–96.
   PubMed Web of Science ®Google Scholar
• Park JY, Lee SH, Shin MJ, Hwang GS. 2015. Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One. 10(8):e0135228
   PubMed Web of Science ®Google Scholar
• Pedrini M, Massuda R, Fries GR, de Bittencourt Pasquali MA, Schnorr CE, Moreira JCF, Teixeira AL, Lobato MIR, Walz JC, Belmonte-de-Abreu PS, et al. 2012. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res. 46(6):819–824.
   PubMed Web of Science ®Google Scholar
• Ponizovsky AM, Modai I, Nechamkin Y, Barshtein G, Ritsner MS, Yedgar S, Lecht S, Bergelson LD. 2001. Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology. Schizophr Res. 52(1–2):121–126.
   PubMed Web of Science ®Google Scholar
• Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT-J, Griffin JL, Wayland M, Freeman T, Dudbridge F, Lilley KS, et al. 2004. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 9(7):684–697.
   PubMed Web of Science ®Google Scholar
• Reichel M, Hönig S, Liebisch G, Lüth A, Kleuser B, Gulbins E, Schmitz G, Kornhuber J. 2015. Alterations of plasma glycerophospholipid and sphingolipid species in male alcohol-dependent patients. Biochim Biophys Acta. 1851(11):1501–1510.
   PubMed Web of Science ®Google Scholar
• Roberts LD, Souza AL, Gerszten RE, Clish CB. 2012. Targeted metabolomics. Curr Protoc Mol Biol. 98(1):30.2.1–30.2.24.
   Google Scholar
• Salim S. 2014. Oxidative stress and psychological disorders. Curr Neuropharmacol. 12(2):140–147.
   PubMed Web of Science ®Google Scholar
• Sastry PS. 1985. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res. 24(2):69–176.
   PubMed Web of Science ®Google Scholar
• Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz WF. 2004. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol Psychiatry. 56(1):41–45.
   PubMed Web of Science ®Google Scholar
• Schmitz G, Ruebsaamen K. 2010. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 208(1):10–18.
   PubMed Web of Science ®Google Scholar
• Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S. 2008. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res. 7(10):4266–4277.
   PubMed Web of Science ®Google Scholar
• Sekas G, Patton GM, Lincoln EC, Robins SJ. 1985. Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J Lab Clin Med. 105(2):190–194.
   PubMed Web of Science ®Google Scholar
• Sethi S, Brietzke E. 2015. Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders. Int J Neuropsychopharmacol. 19(3):pyv096.
   PubMed Web of Science ®Google Scholar
• Sethi S, Hayashi MA, Barbosa BS, Pontes JG, Tasic L, Brietzke E. 2017a. Lipidomics, biomarkers, and schizophrenia: a current perspective. Adv Exp Med Biol. 965:265–290.
   PubMedGoogle Scholar
• Sethi S, Hayashi MA, Sussulini A, Tasic L, Brietzke E. 2017b. Analytical approaches for lipidomics and its potential applications in neuropsychiatric disorders. World J Biol Psychiatry. 18(7):506–520.
   PubMed Web of Science ®Google Scholar
• Skosnik PD, Yao JK. 2003. From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia? Prostaglandins Leukot Essent Fatty Acids. 69(6):367–384.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Diczfalusy U, Lindholm B, Heimburger O. 2004. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant. 19(4):972–976.
   PubMed Web of Science ®Google Scholar
• Tessier C, Sweers K, Frajerman A, Bergaoui H, Ferreri F, Delva C, Lapidus N, Lamaziere A, Roiser JP, De Hert M, et al. 2016. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations. Transl Psychiatry. 6(10):e906.
   PubMed Web of Science ®Google Scholar
• van der Kemp WJ, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. 2012. A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia. Schizophr Res 141(2–3):153–161.
   PubMed Web of Science ®Google Scholar
• Vance JE, Tasseva G. 2013. Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells. Biochim Biophys Acta. 1831(3):543–554.
   PubMed Web of Science ®Google Scholar
• Wang D, Cheng SL, Fei Q, Gu H, Raftery D, Cao B, Sun X, Yan J, Zhang C, Wang J, et al. 2019. Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia. Psychiatry Res. 272:18–29.
   PubMed Web of Science ®Google Scholar
• Warensjo E, Ohrvall M, Vessby B. 2006. Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Nutr Metab Cardiovasc Dis. 16(2):128–136.
   PubMed Web of Science ®Google Scholar
• Weber-Fahr W, Englisch S, Esser A, Tunc-Skarka N, Meyer-Lindenberg A, Ende G, Zink M. 2013. Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study. Psychiatry Res. 214(3):365–373.
   PubMed Web of Science ®Google Scholar
• Wood PL, Holderman NR. 2015. Dysfunctional glycosynapses in schizophrenia: disease and regional specificity. Schizophr Res. 166(1–3):235–237.
   PubMed Web of Science ®Google Scholar
• Wood PL, Unfried G, Whitehead W, Phillipps A, Wood JA. 2015. Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia. Schizophr Res. 161(2–3):506–510.
   PubMed Web of Science ®Google Scholar
• Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, et al. 2013. Potential metabolite markers of schizophrenia. Mol Psychiatry. 18(1):67–78.
   PubMed Web of Science ®Google Scholar
• Yang X, Sun L, Zhao A, Hu X, Qing Y, Jiang J, Yang C, Xu T, Wang P, Liu J, et al. 2017. Serum fatty acid patterns in patients with schizophrenia: a targeted metabonomics study. Transl Psychiatry. 7(7):e1176.
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy R. 2006. Altered glutathione redox state in schizophrenia. Dis Markers. 22(1–2):83–93.
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy RD. 2000. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res. 42(1):7–17.
   PubMed Web of Science ®Google Scholar